SAB BIOTHERAPEUTICS, INC. (SABS) Return on equity 2020–2025
SAB BIOTHERAPEUTICS, INC. (SABS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
8.8%FY2025 · since FY2020: 51.6% → 8.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.8% | +140.1 pp |
| FY2024 | -131.3% | -57.7 pp |
| FY2023 | -73.6% | -13.3 pp |
| FY2022 | -60.3% | -15.9 pp |
| FY2021 | -44.5% | -96.0 pp |
| FY2020 | 51.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SABS financial trends
SABS RevenueSABS Net incomeSABS Net marginSABS Gross profitSABS Gross marginSABS Operating incomeSABS Operating marginSABS Operating cash flowSABS Free cash flowSABS Capital expendituresSABS Stock buybacksSABS Dividends paidSABS Total assetsSABS Total liabilitiesSABS Shareholders’ equitySABS overview →